THC Composition for Cytokine Storm and Macrophage Modulation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing pharmacological interventions are inadequate for managing chronic inflammation, which contributes to various chronic diseases and disorders, and there is a need for effective treatments for conditions like COVID-19, acute respiratory failure, and other inflammatory responses.

Innovation Solution

Compositions comprising tetrahydrocannabinol (THC) and optionally fluvoxamine, melatonin, interferon, or acetylcysteine, which modulate macrophage phenotype by interacting with CB2 and sigma-1 receptors, inhibit pro-inflammatory cytokines, and promote anti-inflammatory cytokines, thereby reducing inflammation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional pharmacological interventions are used to manage inflammation, then some inflammatory conditions can be treated, but they are inadequate for managing chronic inflammation and cytokine storms

Engineering Contradiction:

Improveeffectiveness of anti-inflammatory treatmentVSAvoidapplicability to various inflammatory conditions

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent changes the chemical parameter by using THC instead of conventional anti-inflammatory drugs. THC interacts with CB2 receptors and sigma-1 receptors to modulate macrophage phenotype, inhibit pro-inflammatory cytokines, and promote anti-inflammatory cytokines, providing a novel mechanism of action that is more effective for chronic inflammation and cytokine storms

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates a composite therapeutic approach by combining THC with other compounds that have different mechanisms of action. This composite composition addresses multiple inflammatory pathways simultaneously, improving both reliability and adaptability across various inflammatory conditions including COVID-19, acute respiratory failure, and chronic inflammatory diseases

Inventive Principle:

Principle #40Composite materials

2Reliability

If THC and combination compositions are used to treat inflammatory conditions, then inflammation and cytokine storms are effectively reduced, but the complexity of the composition increases

Engineering Contradiction:

Improveanti-inflammatory efficacyVSAvoidcomposition complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent segments the complex inflammatory response into multiple targetable pathways by using THC to specifically modulate macrophage phenotype through CB2 and sigma-1 receptors. This segmentation allows for targeted intervention at specific points in the inflammatory cascade, improving efficacy while managing composition complexity through mechanism-based targeting

Inventive Principle:

Principle #1Segmentation

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The compositions effectively reduce inflammation and cytokine storms, treating conditions such as COVID-19, acute respiratory distress syndrome, and other inflammatory disorders by altering macrophage phenotype and suppressing excessive cytokine production.

Implementation Method 1

modulate macrophage phenotype by interacting with CB2 and sigma-1 receptors

Methodology Applied

Scientific EffectReceptor interaction:

Implementation Method 2

modulate macrophage phenotype by interacting with CB2 and sigma-1 receptors

Methodology Applied

Scientific EffectReceptor interaction:

Implementation Method 3

inhibit pro-inflammatory cytokines, and promote anti-inflammatory cytokines, thereby reducing inflammation

Methodology Applied

Scientific EffectCytokine inhibition:

Implementation Method 4

inhibit pro-inflammatory cytokines, and promote anti-inflammatory cytokines, thereby reducing inflammation

Methodology Applied

Scientific EffectCytokine promotion:

Data Source

PatentUS20250352561A1Compositions and methods using tetrahydrocannabinol and compositions including same for treating indications involving inflammation

Publication Date: 2025.11.20 NAGY AURANGZEB NAFEES

AI summary

Compositions and methods for treating any one of the disclosed indications involving inflammation in a subject in need thereof, which includes administering to the subject a therapeutically effective amount of a composition including a tetrahydrocannabinol (THC) constituent. The composition is beneficial in reducing inflammation and/or inhibiting the production of pro-inflammatory cytokines and/or converting inflammatory M1 phenotype macrophages into anti-inflammatory M2 phenotype macrophages. It is useful in treating indications such as COVID-19, PASC/long COVID, effects related to ROSC, exposure to chemical or biological weapons, chemotherapy side effects, graft versus host disease, kidney damage from inflammation, chronic obstructive pulmonary disease, aging, and ARDS resulting from COVID-19, mechanical ventilation, shock, sepsis. In further embodiments, the composition may further include fluvoxamine, melatonin, or other disclosed constituents.